Although it is assumed that these checkpoint blockade therapies primarily rescue T cell's anti-tumor efficacy, increasing evidence suggests that NK cells potentially respond to PD-1/PD-L1 blockade, particularly for MHC I-deficient tumors, as evidenced by attenuated anti-tumor efficacy after depletion of NK cells (70). This evidence concerns the gene PDCD1 and neoplasm.